These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21887679)

  • 1. A phase 2 randomized multicenter study of 2 extended dosing schedules of oral ezatiostat in low to intermediate-1 risk myelodysplastic syndrome.
    Raza A; Galili N; Smith SE; Godwin J; Boccia RV; Myint H; Mahadevan D; Mulford D; Rarick M; Brown GL; Schaar D; Faderl S; Komrokji RS; List AF; Sekeres M
    Cancer; 2012 Apr; 118(8):2138-47. PubMed ID: 21887679
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS).
    Raza A; Galili N; Mulford D; Smith SE; Brown GL; Steensma DP; Lyons RM; Boccia R; Sekeres MA; Garcia-Manero G; Mesa RA
    J Hematol Oncol; 2012 Apr; 5():18. PubMed ID: 22546242
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1-2a multicenter dose-escalation study of ezatiostat hydrochloride liposomes for injection (Telintra, TLK199), a novel glutathione analog prodrug in patients with myelodysplastic syndrome.
    Raza A; Galili N; Callander N; Ochoa L; Piro L; Emanuel P; Williams S; Burris H; Faderl S; Estrov Z; Curtin P; Larson RA; Keck JG; Jones M; Meng L; Brown GL
    J Hematol Oncol; 2009 May; 2():20. PubMed ID: 19439093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II multicenter study of arsenic trioxide in patients with myelodysplastic syndromes.
    Schiller GJ; Slack J; Hainsworth JD; Mason J; Saleh M; Rizzieri D; Douer D; List AF
    J Clin Oncol; 2006 Jun; 24(16):2456-64. PubMed ID: 16651647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome.
    Raza A; Galili N; Smith S; Godwin J; Lancet J; Melchert M; Jones M; Keck JG; Meng L; Brown GL; List A
    Blood; 2009 Jun; 113(26):6533-40. PubMed ID: 19398716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study.
    Vey N; Bosly A; Guerci A; Feremans W; Dombret H; Dreyfus F; Bowen D; Burnett A; Dennis M; Ribrag V; Casadevall N; Legros L; Fenaux P
    J Clin Oncol; 2006 Jun; 24(16):2465-71. PubMed ID: 16651646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
    Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
    Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes.
    Lyons RM; Cosgriff TM; Modi SS; Gersh RH; Hainsworth JD; Cohn AL; McIntyre HJ; Fernando IJ; Backstrom JT; Beach CL
    J Clin Oncol; 2009 Apr; 27(11):1850-6. PubMed ID: 19255328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of response to therapy with ezatiostat in lower risk myelodysplastic syndrome.
    Galili N; Tamayo P; Botvinnik OB; Mesirov JP; Brooks MR; Brown G; Raza A
    J Hematol Oncol; 2012 May; 5():20. PubMed ID: 22559819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oral Ezatiostat HCl (TLK199) and Myelodysplastic syndrome: a case report of sustained hematologic response following an abbreviated exposure.
    Quddus F; Clima J; Seedham H; Sajjad G; Galili N; Raza A
    J Hematol Oncol; 2010 Apr; 3():16. PubMed ID: 20416051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
    Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
    Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
    Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Delaunay J; Banos A; Blanc M; Vey N; Schmidt A; Visanica S; Eclache V; Turlure P; Beyne-Rauzy O; Guerci A; Delmer A; de Botton S; Rea D; Fenaux P; Adès L
    Leuk Res; 2011 Nov; 35(11):1444-8. PubMed ID: 21715006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life.
    Balducci L
    Cancer; 2006 May; 106(10):2087-94. PubMed ID: 16607649
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study.
    Balleari E; Rossi E; Clavio M; Congiu A; Gobbi M; Grosso M; Secondo V; Spriano M; Timitilli S; Ghio R
    Ann Hematol; 2006 Mar; 85(3):174-80. PubMed ID: 16408206
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclosporin A and thalidomide in patients with myelodysplastic syndromes: Results of a pilot study.
    Xiao Z; Xu Z; Zhang Y; Qin T; Zhang H; Fang L
    Leuk Res; 2011 Jan; 35(1):61-5. PubMed ID: 20591481
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of transfusional iron overload in patients with myelodysplastic syndrome or severe anemia: data from multicenter clinical practices.
    Raptis A; Duh MS; Wang ST; Dial E; Fanourgiakis I; Fortner B; Paley C; Mody-Patel N; Corral M; Scott J
    Transfusion; 2010 Jan; 50(1):190-9. PubMed ID: 19719471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lenalidomide and Prednisone in Low and Intermediate-1 IPSS Risk, Non-Del(5q) Patients With Myelodysplastic Syndromes: Phase 2 Clinical Trial.
    Komrokji RS; Al Ali NH; Padron E; Cogle C; Tinsley S; Sallman D; Lancet JE; Lis AF
    Clin Lymphoma Myeloma Leuk; 2019 Apr; 19(4):251-254. PubMed ID: 30852241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable long-term responses in patients with myelodysplastic syndromes treated with lenalidomide.
    Kurtin SE; List AF
    Clin Lymphoma Myeloma; 2009 Jun; 9(3):E10-3. PubMed ID: 19525184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.